TOP

内科・消化器内科 さいとう内科クリニック

実績一覧

2017年

  1. 斉藤 雅也 肝硬変・肝癌患者の栄養療法(3) 肝硬変患者に対するカルニチン補充療法の意義 臨床消化器内科2017; 32(5): 573-579.

2016年

  1. Masaya Saito, Hirotaka Hirano, Yoshihiko Yano, Kenji Momose, Masaru Yoshida, Takeshi Azuma. Serum level of taurine would be associated with the amelioration of minimal hepatic encephalopathy in cirrhotic patients. Hepatol Res 2016; 46(2): 215-224. DOI: 10.1111/hepr.12565.
  2. Masaya Saito, Yoshihiko Yano, Hirotaka Hirano, Kenji Momose, Kentaro Mouri, Akitoyo Hishimoto, Masaru Yoshida, Takeshi Azuma. The serum level of NX-DCP-R, but not DCP, is not increased in alcoholic liver disease without hepatocellular carcinoma. Cancer Biomark 2016; 16(1): 171-180. DOI: 10.3233/CBM-150553.

2015年

  1. Masaya Saito, Yoshihiko Yano, Hirotaka Hirano, Kenji Momose, Yuki Kawano, Masaru Yoshida, Takeshi Azuma. Visceral fat accumulation is associated with increased mortality rate after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. J Cancer Ther, 2015 Dec 3. DOI: 10.4236/jct.2015.613122
  2. Masaya Saito, Hirotaka Hirano, Yoshihiko Yano, Hiroki Hayashi, Kenji Momose, Akihiro Minami, Yuki Kawano, Masaru Yoshida, Takeshi Azuma. Recent advances of diagnosis and treatment in minimal hepatic encephalopathy of cirrhotic patients in Japan. Journal of Hepatitis 2015; 1: 1-3.
  3. Yuki Kawano, Shin Nishiumi, Masaya Saito, Yoshihiko Yano, Takeshi Azuma, Masaru Yoshida. Identification of Lipid Species Linked to the Progression of Non-alcoholic Fatty Liver Disease. Curr Drug Targets. 2015; 16(12): 1293-1300. DOI: 10.2174/1389450116666150408103318.
  4. Masaya Saito, Yoshihiko Yano, Hirotaka Hirano, Kenji Momose, Masaru Yoshida, Takeshi Azuma. Serum NX-DCP is a new noninvasive model for predicting significant liver fibrosis in chronic hepatitis C. Hepat Mon 2015; 15(2): e22978, DOI: 10.5812/hepatmon.22978
  5. Hirotaka Hirano, Masaya Saito, Yoshihiko Yano, Kenji Momose, Masaru Yoshida, Atsushi Tanaka, Takeshi Azuma. Chronic liver disease questionnaire would be a primary screening tool of neuropsychiatric test detecting minimal hepatic encephalopathy of cirrhotic patients. Hepatol Res 2015; 45(9): 939-1046.

2014年

  1. Fugui Bai, Yoshihiko Yano, Soo-Ryang Kim, Yasushi Seo, Akira Miki, Masaya Saito, Hirotaka Hirano, Kenji Momose, Akihiro Minami, Yuri Hatazawa, Takanobu Hayakumo, Dewiyani Widasari, Hanggoro Tri Rinonce, Masahiko Sugano, Satoshi Tani, Seitetsu Yoon, Susumu Imoto, Takeshi Azuma, Hak Hotta, Yoshitake Hayashi. Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group. Int J Mol Med 2014; 33(6): 1652-6.
  2. Masaya Saito, Yoshihiko Yano, Akihiro Minami, Hirotaka Hirano, Kenji Momose, Maki Sugimoto, Masaru Yoshida, Takeshi Azuma. Branched-chain amino acid granules improve non-protein respiratory quotient after radiofrequency ablation. Intern Med 2014; 53(14): 1469-75.
  3. Masaya Saito, Yoshihiko Yano, Akihiro Minami, Kenji Momose, Hirotaka Hirano, Takashi Yamasaki, Tomoo Itoh, Masaru Yoshida, Takeshi Azuma. Autoimmune-associated hemophagocytic syndrome originating from autoimmune hepatitis with a successful response to therapy: a case report. Intern Med 2014; 53(2): 103-107.

2013年

  1. Fugui Bai, Yoshihiko Yano, Takumi Fukumoto, Atsushi Takebe, Motofumi Tanaka, Kaori Kuramitsu, Nungki Anggorowati, Hanggoro Tri Rinonce, Dewiyani Widasari, Masaya Saito, Hirotaka Hirano, Takanobu Hayakumo, Yasushi Seo, Takeshi Azuma, Yonson Ku, Yoshitake Hayashi. Quantification of Pregenomic RNA and Covalently Closed Circular DNA in Hepatitis B Virus-Related Hepatocellular Carcinoma. Int J Hepatol 2013; 849290. DOI: 10.1155/2013/849290.
  2. Masaya Saito, Yasushi Seo, Yoshihiko Yano, Kenji Momose, Hirotaka Hirano, Masaru Yoshida, Takeshi Azuma. Serum albumin and prothrombin time before entecavir treatment in chronic hepatitis B or cirrhosis are related to amelioration of liver function after treatment. Eur J Gastroenterol Hepatol 2013; 25(12): 1369-76.
  3. Masaya Saito, Yasushi Seo, Yoshihiko Yano, Keiichiro Uehara, Shigeo Hara, Kenji Momose, Hirotaka Hirano, Hiroshi Yokozaki, Masaru Yoshida, Takeshi Azuma. Portal venous tumor growth- type of hepatocellular carcinoma without liver parenchyma tumor nodules: a case report. Ann Hepatol 2013; 12(6): 969-973.
  4. Masaya Saito, Yasushi Seo, Yoshihiko Yano, Kenji Momose, Hirotaka Hirano, Masaru Yoshida, Takeshi Azuma. Reduction in non-protein respiratory quotient is related to overall survival after hepatocellular carcinoma treatment. PLoS One 2013; 8: e55441. DOI: 10.1371/journal.pone.0055441.
  5. Hirotaka Hirano, Masaya Saito, Yasushi Seo, Yoshihiko Yano, Takeshi Azuma. NX-DCP as a novel biomarker would be related to liver function in cirrhotic patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2013; 25(6): 748-749.
  6. Masaya Saito, Yasushi Seo, Yoshihiko Yano, Kenji Momose, Hirotaka Hirano, Masaru Yoshida, Takeshi Azuma. Successful treatment by coil embolization of symptomatic intrahepatic portosystemic venous shunt through a patent ductus venosus in a non-cirrhotic adult: a case report. Intern Med 2013; 52(5): 555-559.

2012年

  1. Masaya Saito, Yasushi Seo, Yoshihiko Yano, Akira Miki, Kenji Momose, Hirotaka Hirano, Masaru Yoshida, Takeshi Azuma. Alteration of non-protein respiratory quotient after hepatocellular carcinoma treatment can be related to des-γ-carboxy prothrombin before treatment. SpringerPlus 2012; 1: 55.
  2. Yoshihiko Yano, Yasushi Seo, Akira Miki, Masaya Saito, Hirotaka Kato, Ken-Ichi Hamano, Manabu Oya, Sachiko Ouchi, Takashi Fujisawa, Hajime Yamada, Yukimasa Yamashita, Satoshi Tani, Shigeya Hirohata, Seitetsu Yoon, Naoto Kitajima, Kazunari Kitagaki, Akira Kawara, Takatoshi Nakashima, Hosai Yu, Tetsuo Maeda, Takeshi Azuma, Ahmed El-Shamy, Hak Hotta, Yoshitake Hayashi, Kobe Hepatitis Therapeutic Group. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. Int J Mol Med 2012; 30(5): 1048-1052.
  3. Masaya Saito, Yasushi Seo, Yoshihiko Yano, Akira Miki, Yukiko Morinaga, Tomoo Itoh, Masaru Yoshida, Takeshi Azuma. A Hepatocellular Carcinoma Developed Following 18 Years from Sustained Virological Response to Interferon Therapy in a Patient with Chronic Hepatitis C: Case Report and Literature Review. Clin J Gastroenterol 2012; 5(2): 119-126.
  4. Masaya Saito, Yasushi Seo, Yoshihiko Yano, Akira Miki, Masaru Yoshida, Takeshi Azuma. A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment. J Gastroenterol 2012; 47(10): 1134-1142.
  5. Masaya Saito, Yasushi Seo, Yoshihiko Yano, Akira Miki, Yukiko Morinaga, Tomoo Itoh, Masaru Yoshida, Takeshi Azuma. Sonazoid-enhanced ultrasonography and Ga-EOB-DTPA-enhanced MRI of hepatic inflammatory pseudotumor: a case report. Intern Med 2012; 51(7): 723-6.
  6. Masaya Saito, Yasushi Seo, Yoshihiko Yano, Akira Miki, Masaru Yoshida, Takeshi Azuma. Short-term reductions in non-protein respiratory quotient and prealbumin can be associated with the long-term deterioration of liver function after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. J Gastroenterol 2012; 47(6): 704-14.
  7. Masaya Saito, Yasushi Seo, Yoshihiko Yano, Akira Miki, Kenji Momose, Hirotaka Hirano, Masaru Yoshida, Takeshi Azuma. Liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolization. Aliment Pharmacol Ther 2012; 35(7): 861-2.
  8. 斉藤 雅也、瀬尾 靖、矢野 嘉彦、三木 章、吉田 優、東 健 肝細胞癌患者における経カテーテル的肝動脈塞栓術後の肝機能悪化の早期予測と有用性 消化と吸収2012; 34: 254-261.

2011年

  1. 井上 潤、増田 充弘、斉藤 雅也、斧山 美津子、塩見 英之、外山 博近、新関 亮、松本 逸平、林 祥剛、牧野 哲哉、多田 秀敏、久津見 弘、具 英成、東 健 膵切除後に残膵に再燃をきたした自己免疫性膵炎の2例 日本消化器病学会雑誌2011; 108: 640-649.
  2. 竹内 庸浩、多田秀敏、西田 悠、野村 祐介、牧野 哲哉、前田 哲男、斉藤 雅也、林 祥剛 C型慢性肝炎に対するインターフェロン治療著効16年後に急速発育を示した肝細胞癌の1症例 肝胆膵2011; 63: 699-705.

スマートフォンで当院ホームページをご覧いただく際はQRコードを読み取っていただくと便利です

気軽にお問い合わせください 078-967-0019
固定電話が繋がりにくい時は 080-7097-5109